The ASX 200 slid to six month lows today, down 1.34% at 6,939 just before market close with all sectors ending lower except Health Care. Energy stocks were.
Clinical-stage drug development company Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) has taken a leap forward in the fight against pancreatic ductal adenocarcinoma.
The ASX has logged a stellar day, with the benchmark S&P/ASX 200 finishing up 1.19%, or 86 points, to 7,297 after news that July inflation had cooled more.
ASX futures are pointing to a modest 0.35% or 25-point lift in trading today, having climbed 0.63% or 44.6 points yesterday. In the US, the Dallas Fed.
Pharmaxis (OTCMKTS:PXSLY – Get Free Report) and Theravance Biopharma (NASDAQ:TBPH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability. Earnings & Valuation This table compares Pharmaxis and […]